BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
Items 501–600 of 894
Immune checkpoint modulating T cells and NK cells response to Mycobacterium tuberculosis infection
Qin, Y., Wang, Q., & Shi, J. (2023) · Microbiological Research · doi:10.1016/j.micres.2023.127393 · Cited by 20
Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response
Aquino, A., Bianchi, N., Terrazzan, A., & Franzese, O. (2023) · Biology · doi:10.3390/biology12081047 · Cited by 24
Heidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19
“BTLA negatively regulates T cells’ activation via association with the SHP-1 and SHP-2, but the down-stream signaling pathway has not yet been elucidated [119].”
Gill, G. S., Kharb, S., Goyal, G., Das, P., Kurdia, K. C., Dhar, R., & Karmakar, S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2504906 · Cited by 24
“BtlA (cD272), described over two decades ago as a th1-specific transcript and resembles PD-1 and ctlA-4 in both form and function [120,121]. its principal ligand is herpesvirus entry mediator (HveM) but, also interacts with cD160, lymphotoxin-alpha (lt-α), tNF-SF, and liGHt (lympho-toxin homolog,…”
Rodríguez-Barbosa, J.-I., Fernández‐Renedo, C., Bravo, A., Bühler, L. H., & del Rio, M. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.101 · Cited by 21
Considering B7-CD28 as a family through sequence and structure
West, S. M., & Deng, X. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219855970 · Cited by 22
“To illustrate this, NKp30 was initially identified on NK cells, without any notable relationship to the B7-CD28 family.54 A decade later, a previously unannotated gene with a sequence identity “comparable” to other B7 members, therefore named B7-H6 (NCR3LG1), was identified as its receptor.31 Consequently, NKp30 is no…”
BackgroundShi, W. M., Shao, T., Li, J., Fan, D., Lin, A., Xiang, L., & Shao, J.-Z. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900458 · Cited by 19
“of Grb2 and Src homology phosphatase-1/-2 (6).”
BackgroundKarakatsanis, S., Bertsias, G. K., Roussou, P. A., & Boumpas, D. T. (2013) · Hematological Oncology · doi:10.1002/hon.2098 · Cited by 21
“BTLA expression is induced during activation of T cells, and BTLA remains expressed on T helper 1 (Th1) cells but not Th2 cells [15], perhaps providing a means for specific control for this cell subset.”
BackgroundPeter, H. H., & Warnatz, K. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.s61 · Cited by 19
“7 B and T cell lymphocyte attenuator BTLA expression occurs preferentially on Th1 cells ∼ 48 h after activation [45], but BTLA transcripts were also detected in”
BackgroundBTLA, a new inhibitory B7 family receptor with a TNFR family ligand.
Zeng, C., Wu, T., Yu, Z., Xia, X. P., & Zhao, Y. X. (2005) · PubMed · Cited by 19
Ward, F. J., Dahal, L. N., & Eid, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02182 · Cited by 19
“Other checkpoints include PD1 (CD279) (28, 29), ICOS (CD278) (30), 4-1BB (CD137) (31), OX40 (CD134) (32), LAG-3 (CD223) (33), TIM-3 (34), TIGIT (35), VISTA (36), BTLA (CD272) (37), and GITR (38), which display a hierarchy of expression on different cell types and therefore exert a more selective control over interacti…”
BackgroundMartín, P., Blanco-Domínguez, R., & Sánchez‐Díaz, R. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00586-4 · Cited by 18
“OVERVIEW OF THE IMMUNOMODULATORY RECEPTORS EXPRESSED BY T CELLS PD1, CTLA-4, and BTLA belong to the CD28 Ig superfamily and share similar protein structures.(5) PD-1 (CD279) is expressed by all T cells during activation, B cells, natural killer, and myeloid cells.”
BackgroundDong, X., Song, J., Chen, B., Qi, Y., Jiang, W., Li, H., Zheng, D., Wang, Y., Zhang, X., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.592811 · Cited by 19
“BTLA is also a member of the CD28 immunoglobulin superfamily, which includes CTLA-4, CD28, inducible costimulatory molecule (ICOS), and PD-1 (18).”
BackgroundInfluentialImmune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes
Cocco, C., Morandi, F., & Airoldi, I. (2021) · Cells · doi:10.3390/cells10040927 · Cited by 18
“Binding of BTLA to HVEM has been shown to recruit Src homology 2 domain-containing protein tyrosine phosphatase (SHP)-1 and -2 proteins, resulting in suppression of T cell receptor (TCR) activation [203,207].”
BackgroundYang, C., Blaize, G., Marrocco, R., Rouquié, N., Bories, C., Gador, M., Mélique, S., Joulia, E., Benamar, M., Dejean, A. S., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abl5343 · Cited by 19
The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies
Weber, J. S. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232292.06785.a3 · Cited by 18
T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis
Zheng, C., Shi, Y., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1081999 · Cited by 21
del Rio, M., Seebach, J. D., Fernández‐Renedo, C., & Rodríguez-Barbosa, J.-I. (2013) · Xenotransplantation · doi:10.1111/xen.12049 · Cited by 17
Deppong, C. M., Parulekar, A. D., Boomer, J. S., Bricker, T. L., & Green, J. M. (2010) · European Journal of Immunology · doi:10.1002/eji.200940282 · Cited by 17
Association of BTLA rs1982809 polymorphism with lung cancer risk in Tunisian population
Khadhraoui, C., Kaabachi, W., Tritar, F., Daghfous, H., Hamzaoui, K., & Hamzaoui, A. (2020) · International Journal of Immunogenetics · doi:10.1111/iji.12491 · Cited by 19
Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus
Stefanski, A., & Dörner, T. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000825 · Cited by 21
“BTLA is also a member of the CD28superfamily, similar to PD-1 and CTLA-4 in terms of its structure and function [56].”
BackgroundThe role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants
Thangavelu, G., MURPHY, K. M. M., Yagita∥, H., Boon, L., & Anderson, C. C. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.01.007 · Cited by 17
“2008) and increased susceptibility to experimental utoimmune encephalomyelitis (Watanabe et al. 2003) and alleric airway inflammation (Deppong et al.”
BackgroundSelf-citationB7-H4 Induces Donor-Specific Tolerance in Mouse Islet Allografts
Wang, X., Hao, J., Metzger, D. L., Mui, A., Ao, Z., Verchere, C. B., Chen, L., Ou, D., & Warnock, G. L. (2011) · Cell Transplantation · doi:10.3727/096368911x582750 · Cited by 17
Murase, W., Kamakura, Y., Kawakami, S., Yasuda, A., Wagatsuma, M., Kubota, A., Kojima, H., Ohta, T., Takahashi, M., Mutoh, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413620 · Cited by 18
“BTLA (CD272) has been reported as one of the CD28 immunoglobulin superfamily expressed on all lymphocytes and a type I transmembrane co-signaling receptor attenuating T cell function [46].”
Owada, T., Watanabe, N., Oki, M., Oya, Y., Saito, Y., Saito, T., Iwamoto, I., Murphy, T. L., MURPHY, K. M. M., & Nakajima, H. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0309138 · Cited by 18
“mBTLA-RV was described previously [5].”
BackgroundMethodInfluentialSelf-citationKallinich, T., Beier, K. C., Gelfand, E. W., Kroczek, R. A., & Hamelmann, E. H. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02369.x · Cited by 22
BTLA and HVEM: Emerging players in the tumor microenvironment and cancer progression
Mohamed, A. H., Obeid, R. A., Fadhil, A. A., Amir, A. A., Adhab, Z. H., Jabouri, E. A., Ahmad, I. S., & Alshahrani, M. Y. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156412 · Cited by 18
The Role of OX40–OX40L Axis in the Pathogenesis of Atopic Dermatitis
Schettini, N., Pacetti, L., Corazza, M., & Borghi, A. (2024) · Dermatitis · doi:10.1089/derm.2024.0058 · Cited by 17
“100 An in vitro cellular study demonstrated an overexpression of BTLA in T follicular helper cells after co-culture with DCs activated by TSLP. 101 Trials evaluating the ef fi cacy and safety of BTLA agonist are currently in a recruiting phase (NCT05935085).”
Mélique, S., Yang, C., & Lesourne, R. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.03.008 · Cited by 17
“[17] Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al.”
BackgroundB7x in cancer immunity and immunotherapy
Mortezaee, K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110133 · Cited by 18
Demberg, T., Mohanram, V., Musich, T., Brocca‐Cofano, E., McKinnon, K. M., Venzon, D. J., & Robert-Guroff, M. (2015) · Virology · doi:10.1016/j.virol.2015.06.022 · Cited by 16
“The B and T lymphocyte attenuator (BTLA, CD272), a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 on T cells (Watanabe et al., 2003) was highly expressed on CD21hi splenic MZ B cells (Table 2, Fig.”
BackgroundRationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy
Mandalà, M., Tondini, C. A., Merelli, B., & Massi, D. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0282-0 · Cited by 16
Barham, M. S., Abrahams, D. A., Khayumbi, J., Ongalo, J., Tonui, J., Campbell, A., de Kock, M., Ouma, S. G., Odhiambo, F. H., Hanekom, W. A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01983 · Cited by 16
“BTLA was defined as an inhibitory receptor containing two immunoreceptor tyrosine-based inhibition motifs (ITIMs) in its cytoplasmic tail that is functionally and structurally similar to CTLA-4 and PD-1 (44).”
BackgroundInfluentialXia, L., Zhang, S., Zhou, J., & Li, Y. (2010) · PubMed Central · Cited by 19
New battlefields for costimulation
Martín‐Orozco, N., & Dong, C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060219 · Cited by 16
“Recently several novel costimulatory receptors have been shown to negatively regulate T cell activation, in cluding the CD28 family molecules pro grammed death (PD)-1 (1), which binds PD-1 ligand (PD-L1; also known as B7-H1) and PD-L2 (also known as B7-DC), and B and T lymphocyte attenuator (2), which binds herpesviru…”
Backgrounddel Rio, M., Kurtz, J. M., Pérez‐Martínez, C., Ghosh, A., Pérez‐Simón, J. A., & Rodríguez-Barbosa, J.-I. (2011) · Transplantation · doi:10.1097/tp.0b013e3182339d4a · Cited by 16
“T cells from BTLA-deficient mice are hyperresponsive to anti-CD3-mediated T-cell proliferation (7, 9, 13), and they are more susceptible to autoimmune diseases (14).”
BackgroundJung, S. G., Choi, K. U., Lee, S. D., Lee, Z. Z., & Chung, M. K. (2011) · Korean journal of urology · doi:10.4111/kju.2011.52.2.90 · Cited by 15
Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy
Giuroiu, I., & Weber, J. S. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000241 · Cited by 16
Pelt, D. W. V., Pitchford, L. M., Wang, A. Y., & Horowitz, J. F. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00084.2017 · Cited by 18
“several inflammasome components (36), while BTLA is involved in inhibiting the Th1 “proinflammatory” T-cell response (51).”
BackgroundTormanen, K., Wang, S., Jaggi, U., & Ghiasi, H. (2020) · Journal of Virology · doi:10.1128/jvi.00700-20 · Cited by 15
miR-4759 suppresses breast cancer through immune checkpoint blockade
Lin, Y.-Z., Liu, S., Wu, W., Shen, Y.-C., Wang, Y., Liao, C.-C., Lin, P., Chang, H., Liu, L., Cheng, W., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.12.020 · Cited by 16
Hemmatzadeh, M., Parvin, E. A., Mohammadi, H., Azizi, G., Shomali, N., & Jadidi‐Niaragh, F. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30855 · Cited by 15
Kuncewicz, K., Bojko, M., Battin, C., Karczyńska, A. S., Sieradzan, A. K., Sikorska, E., Wegrzyn, K. E., Wojciechowicz, K., Wardowska, A., Steinberger, P., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115161 · Cited by 16
Yang, X., Zhang, X., Sun, Y., Tu, T., Fu, M. L., Miller, M. L., & Fu, Y. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.05.021 · Cited by 15
“…Listeria-Specific CD8+ Effector and Memory T Cell Responses Previous studies have defined BTLA as a coinhibitory receptor in T cells that inhibits T cell function through its immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (Krieg et al., 2007; Sedy et al., 2005; Watanabe et al., 2003).”
BackgroundAkiyoshi, H., Chung, J., Tomihari, M., Cruz, P. D., & Ariizumi, K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903250 · Cited by 15
Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma
Tang, W., Chen, S., Kang, M., Liu, J., & Liu, C. (2019) · Bioscience Reports · doi:10.1042/bsr20191770 · Cited by 15
Lysosome as the Black Hole for Checkpoint Molecules
Wang, H., Han, X. N., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_14 · Cited by 15
General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology
Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 18
Immune checkpoint for pregnancy
Hu, X., Lai, S., & Liao, A. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-025-01051-y · Cited by 16
Park, S. J., Riccio, R. E., Kopp, S. J., Ifergan, I., Miller, S. D., & Longnecker, R. (2020) · mBio · doi:10.1128/mbio.00790-20 · Cited by 14
“BTLA and CD160 downstream signaling inhibits T cell activation during expression on T cells (28, 45).”
BackgroundThe Lung Adenocarcinoma Microenvironment Mining and Its Prognostic Merit
Zhao, R., Ding, D., Yu, W., Zhu, C., & Ding, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820977547 · Cited by 15
“B and T lymphocyte associated (BTLA) plays a crucial role in the transmission of immunosuppressive signals.(24,25) It has been found to increase the expression of CD4(þ) and CD8(þ) T cells in the pleural fluid of patients with lung cancer and can downregulate the expression of the T cell activation marker CD25 to inhi…”
BackgroundTumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2
Cheng, T., Liu, Y., Yan, H., Xi, Y., Duan, L., Wang, Y., Zhang, T., Gu, Y., Wang, X., Wu, C., et al. (2022) · Cells · doi:10.3390/cells11244021 · Cited by 14
“It has been demonstrated that the BTLA signaling pathway is not the same as PD-1 [10–12], and our results also confirmed this view, making it a potential for combined targeted therapy with PD-1 or PD-L1 for translational importance.”
BackgroundInfluentialGardiner, R., Jahangeer, S. M., Forde, P. F., Ariffin, A. B., Bird, B., Soden, D. M., & Hinchion, J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9550-8 · Cited by 14
B and T Lymphocyte Attenuator Inhibits Antigen-Induced Eosinophil Recruitment into the Airways
Tamachi, T., Watanabe, N., Oya, Y., Kagami, S., Hirose, K., Saito, Y., Iwamoto, I., & Nakajima, H. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000101405 · Cited by 14
“However, the role of BTLA, an inhibitory co-receptor expressed preferentially in Th1 cells and B cells [”
BackgroundSelf-citationWang, Z., Yang, H., Liu, X., Zhang, J., Han, Z., Tao, J., Zhao, C., Ju, X., Tan, R., & Gu, M. (2018) · Medical Science Monitor · doi:10.12659/msm.905752 · Cited by 14
“Histological features of renal tissue obtained from renal transplant recipients with biopsy-proven acute rejection and healthy volunteers. in the cardiac transplantation model, in vivo administration of antagonistic anti-BTLA mAb (Clone 6A6) led to accelerated rejection; more importantly, MHC class II-mismatched cardi…”
BackgroundInfluentialHarnessing Immune Checkpoints for Cancer Therapy
Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 17
Calcium-independent calcineurin regulation
Parry, R. V., & June, C. H. (2003) · Nature Immunology · doi:10.1038/ni0903-821 · Cited by 14
Liao, Z., Lv, X., Liu, S., He, Z., Chen, S., Wang, L., Li, W., & Li, Y. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12850 · Cited by 15
Fate vs Choice: The Immune System Reloaded
MURPHY, K. M. M. (2005) · Immunologic Research · doi:10.1385/ir:32:1-3:193 · Cited by 14
Self-citationInhibitory Receptors of the Immune System: Functions and Therapeutic Implications
Zhang, J., Xiao, X., Liu, W., Demirci, G., & Li, X. C. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.52 · Cited by 13
Associations between CD160 polymorphisms and autoimmune thyroid disease: a case-control study
He, W., Zhao, J., Liu, X., Li, S., Mu, K., Zhang, J., & Zhang, J. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00810-w · Cited by 15
“The binding of LIGHT or LTa to HVEM stimulates costimulatory signals, but the binding of BTLA or CD160 to HVEM initiates co-suppression signals, and thus the CD160/HVEM/LIGHT/BTLA costimulatory/ co-suppression pathway is a bidirectional switch that adjusts T cell activation and takes an important part in regulating im…”
Aubergeon, L., Sawaf, M., Felten, R., Gottenberg, J., Dumortier, H., & Monneaux, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767099 · Cited by 14
“As cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD1), B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor through which immune responses can be negatively regulated (1).”
BackgroundFanale, D., Corsini, L. R., Brando, C., Cutaia, S., Donna, M. C. D., Filorizzo, C., Lisanti, M. C., Randazzo, U., Magrin, L., Romano, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.946319 · Cited by 13
“02 Other immune checkpoints, including B- and T-lymphocyte attenuator (BTLA) (19), butyrophilin sub-family 3 member A1 (BTN3A1) receptor, pan-BTN3A, and butyrophilin sub-family 2 member A1 (BTN2A1) (20), showed an interesting immunomodulatory role in different tumors (11, 21, 22).”
BackgroundYang, M. S., Tian, S., Lin, Z., Fu, Z., & Li, C. (2022) · Medicine · doi:10.1097/md.0000000000031667 · Cited by 14
“[75,76] BTLA-mediated immune inhibition is related to decreased IL-2 production and CD4 + T cell proliferation, but is independent of Treg cell activation.[73,77] B7-H7 also called PD-1H or VISTA, another latest ligand expressed on the surface of monocytes and tumor cells, can inhibit CD4 + and CD8 + T cell function b…”
BackgroundCell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy
Wei, X., & Yang, M. W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180794 · Cited by 15
Qiu, H. N., Wong, C. K., Dong, J., Lam, C. W.-K., & Cai, Z. (2014) · Mediators of Inflammation · doi:10.1155/2014/136463 · Cited by 13
Mining the Complex Family of Protein Tyrosine Phosphatases for Checkpoint Regulators in Immunity
Penafuerte, C., Pérez‐Quintero, L., Vinette, V., Hatzihristidis, T., & Tremblay, M. L. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_68 · Cited by 14
Antigen Presenting Properties of a Myeloid Dendritic-Like Cell in Murine Spleen
Hey, Y. Y., & O'Neill, H. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162358 · Cited by 13
Bulwin, G.-C., Wälter, S., Schlawinsky, M., Heinemann, T., Schulze, A., Höhne, W. E., Krause, G., Kalka-Moll, W. M., Fraser, P. A., Volk, H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001576 · Cited by 13
“). The inhibitory effects induced by TIRC7 ligation could be mediated by the recruitment of the phosphotyrosine phosphatase SHP-1 which plays an important negative regulator role on lymphocyte signaling pathways for a variety of receptors involved in lymphocyte activation”
BackgroundB‐ and T‐Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis
Vendel, A. C., Jaroszewski, L., Linnik, M. D., & Godzik, A. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3282 · Cited by 13
“25,26,30,31 The current study examined the expression profiles of BTLA and HVEM using mass cytometry of peripheral blood mono-nuclear cells (PBMCs) from healthy participants and patients with SLE, as well as gene expression data from patients with SLE obtained from two phase 3 studies (ILLUMINATE-1…”
BackgroundMethodOwoicho, A. M., Ogenyi, D. O., Zhilenkova, A. V., Essogmo, F. E., Tchawe, Y. S. N., Uchendu, I. K., Pascal, A. M., Nikitina, N. M., Rusanov, A. S., Sanikovich, V. D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010265 · Cited by 15
Prinsen, H., de Vries, I. J. M., Torensma, R., Pots, J. M., Mulder, S. F., van Herpen, C. M. L., Elving, L. D., Bleijenberg, G., Stelma, F. F., & van Laarhoven, H. W. M. (2012) · BMC Immunology · doi:10.1186/1471-2172-13-71 · Cited by 17
“Another possible explanation for the decreased number of proliferating T lymphocytes in CFS patients is elevated numbers of co-inhibitory molecules, like programmed death-1, [25,26] cytotoxic T lymphocyte antigen-4, [25] or B and T lymphocyte attenuator [27].”
BackgroundLandscape of transcript isoforms in single T cells infiltrating in non-small-cell lung cancer
Li, J., Comeau, H. Y., Zhang, Z., & Ren, X. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.06.006 · Cited by 12
Zhang, C., Wang, F., Sun, N., Zhang, Z., Zhang, G., Zhang, Z., Luo, Y., Che, Y., Cheng, H., Li, J., et al. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.08.003 · Cited by 12
“BTLA-deficient T cells showed increased proliferation, and BTLA-deficient mice had increased specific antibody responses.(29) Our study showed that a high score was tightly associated with BTLA (Fig.”
BackgroundMansorunov, D., Апанович, Н. В., Апанович, П. В., Кипкеева, Ф. М., Музаффарова, Т. А., Kuzevanova, A. Y., Nikulin, M. P., Malikhova, O. A., & Karpukhin, A. V. (2021) · Diagnostics · doi:10.3390/diagnostics11122370 · Cited by 13
“The B7-H4 receptor is currently not proven; although it is indirectly assumed to be a B and T lymphocyte attenuator (BTLA) [52].”
BackgroundMélique, S., Vadel, A., Rouquié, N., Yang, C., Bories, C., Cotineau, C., Saoudi, A., Fazilleau, N., & Lesourne, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318773121 · Cited by 13
“Briefly, T cells were expanded for 48 h with plate - bound anti - CD3 (145 - 2C11, 5 μ g/mL) and soluble anti - CD28 (PV - 1; 1 μ g/mL) antibodies from BioLegend.”
BackgroundInfluentialThe CD6 interactome orchestrates ligand-independent T cell inhibitory signaling
Santos, R. F., Linhares, A. D. S., Steinberger, P., Davis, S. J., Oliveira, L., & Carmo, A. M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01658-y · Cited by 12
“…that might slightly affect their signaling [47], remain a robust model for investigating T cell activation, and findings in these model cells have significantly validated observations made in primary cells by various research groups investigating CD6 regulation in T cell activation [9, 48– 51].”
BackgroundSchnell, F. J., Alberts‐Grill, N., & Evavold, B. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801798 · Cited by 12
“In addition to directly dampening the tyrosine kinase signaling cascade, SHP-1 may turn off CD8 T cells through its association with inhibitory receptors such as B and T lymphocyte attenuator, PD-1, and CTLA-4 (45).”
BackgroundMixing Signals: Molecular Turn Ons and Turn Offs for Innate γδ T-Cells
Bekiaris, V., Šedý, J. R., & Ware, C. F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00654 · Cited by 16
Wang, X., Wu, M., Shen, X., Zhang, J., Tang, P., Song, H., Liu, X., Huang, Z., & Zhang, X. (2019) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_727_17 · Cited by 12
“BTLA (CD272), an immune checkpoint belonging to Ig superfamily, contains an immunoreceptor tyrosine‐based switch motif and an immunoreceptor tyrosine‐based inhibitory motif in the intracellular domain.[9] BTLA inhibits T cell activation and proliferation through interacting with its unique ligand herpesvirus entry med…”
BackgroundEngineering Anticancer T Cells for Extended Functional Longevity
Pawelec, G., Mariani, E., McLeod, J., Ben‐Yehuda, A., Fülöp, T., Aringer, M., & Barnett, Y. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1297.028 · Cited by 12
Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections
Zhou, D., & Ertl, H. C. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.1.63 · Cited by 12
“The B and T lymphocyte attenuator (BTLA [51]) provides inhibitory signals following binding to the herpes virus entry mediator (HVEM [52]), which is expressed on DCs and also interacts with gD of herpes virus and with distinct regions to two TNF family members, that is, LIGHT and lymphotoxin-A.”
BackgroundSponaas, A., Belyaev, N. N., Falck-Hansen, M., Potocnik, A. J., & Langhorne, J. (2012) · Infection and Immunity · doi:10.1128/iai.00820-12 · Cited by 12
“A combination of reduction in expression of the costimulatory molecule CD86 on DC, lower IL-12 production, and induction of inhibitory interactions via CTLA-4 and BTLA is the most likely explanation for this reduced or anergic CD4 T cell response.”
BackgroundInfluentialZhang, Y., Yang, Y., Zeng, Y., Qu, Q., Shen, D. H., Mu, C., Lei, W., Su, M., Mao, J., Gao, L., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1553042 · Cited by 15
Petrozziello, E., Sayed, A., de Freitas, J. A. T., Federle, C., Nedjic, J., Ravens, S., Akçabozan, B., Schulz, A. M., Zehn, D., Schmidt‐Supprian, M., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02182-y · Cited by 11
“Flow cytometric analysis showed that, in addition to CD5 and CD6, two further negative regulators of TCR signaling (PD-1 and BTLA 34,35 ) also exhibited reduced expression downstream of positive selection in Ctsl ΔTEC Lm54 Tg mice compared to Ctsl +/+ Lm54 Tg mice (Fig.”
Update on hepatitis C virus-specific immunity
Ciuffreda, D., & Kim, A. Y. (2011) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834b879e · Cited by 11
Trez, C. D. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.06.010 · Cited by 11
Nakagomi, D., Suzuki, K., Hosokawa, J., Kobayashi, Y., Suto, A., Takatori, H., Watanabe, N., Matsue, H., Murphy, T. L., MURPHY, K. M. M., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.396 · Cited by 11
“In vivo, it has been shown that BTLA has inhibitory roles in a number of CD4þ T-cell-mediated disease models (Watanabe et al., 2003; Deppong et al., 2006; Tamachi et al., 2007).”
BackgroundMethodSelf-citationZhao, R., Li, Z., Li, C., Xu, K., Zhen, L., Song, W., & Shi, J.-H. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.12.009 · Cited by 11
Wang, J., Chen, Z., Cao, R., Zhang, Q., Chen, T., You, C., Tang, W., & Chen, S. (2021) · BioMed Research International · doi:10.1155/2021/9121824 · Cited by 11
B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection
Ogega, C. O., Skinner, N., Flyak, A. I., Clark, K. E., Nathan L. Board, Björkman, P. J., Crowe, J. E., Cox, A. L., Ray, S. C., & Bailey, J. R. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010179 · Cited by 11
Partyka, A., Woszczyk, D., Strzała, T., Anna, S., Tomkiewicz, A., Frydecka, I., & Karabon, L. (2014) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-014-0300-3 · Cited by 11
“BTLA expression is also significant in mice thymocytes during positive selection (Watanabe et al. 2003).”
BackgroundInfluentialRong, Z., Zhang, F., Wang, Z., He, W., Dong, S., Xu, J., & Dai, F. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0354 · Cited by 12
“17 As suppression of the osteogenic differentiation ability of allo-MSCs in a microenvironment of immune activation has been confirmed, 18 we investigated whether HVEM can inhibit the inflammatory response through binding with BTLA in an allo-MSC-based TEB strategy and promote bone repair.”
Gudi, R. R., Karumuthil‐Melethil, S., Perez, N., Li, G., & Vasu, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-48464-y · Cited by 11
“BTLA, another CD28/CTLA-4 family member, is expressed on activated T and B cells, and its signals can also suppress T-cell response 23 .”
BackgroundInfluentialThe Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Simone, R., & Saverino, D. (2009) · Current Immunology Reviews · doi:10.2174/157339509787314413 · Cited by 11
“In addition, three novel co-stimulatory molecules have been recently identified: inducible co-stimulator (ICOS) providing positive signals, and programmed death-1 (PD-1) and B and T lymphocyte attenuator (BTLA) delivering negative co-stimulatory signals [30, 31].”
BackgroundNegative Immune Checkpoint Inhibitors
Drewniak‐Świtalska, M., Fortuna, P., & Krzystek‐Korpacka, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060713 · Cited by 12
PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease
Kuchroo, J. R., Goldman, N., & Sharpe, A. H. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01296-9 · Cited by 10
“in disease, decreases serum levels of IL-6 and IL-10 and reduces CD4 + T cell production of IL-17A, TNF, IFNγ and IL-10 (ref.”
InfluentialScreening of Crucial Differentially-Methylated/Expressed Genes for Alzheimer’s Disease
Qiu, H., & Weng, Q. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221116220 · Cited by 15
“B and T lymphocyte attenuator, also known as CD272, is a member of CD28 superfamily.(48) It is down-regulated in colorectal cancer and involved in immune cells (CD8 Tcells, CD4 memory resting T cells, resting NK cells, M1 macrophages, etc.”
BackgroundRole of BTLA/HVEM network in development of gastric cancer
Azarafza, M., Tehrani, M., Valadan, R., Maleki, I., Hamedani, S. M. M. G., Ghanadan, A., Alizadeh‐Navaei, R., & Ajami, A. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.07.003 · Cited by 10
Andrzejczak, A., Partyka, A., Wiśniewski, A., Porębska, I., Pawełczyk, K., Ptaszkowski, K., Kuśnierczyk, P., Jasek, M., & Karabon, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006639 · Cited by 11
“BTLA belongs to the immunoglobulin superfamily (Ig SF) and is expressed on the surface of B cells, T cells, natural killer (NK) cells, dendritic cells (DCs), and macrophages (14, 15).”
Background
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.